Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €175.72 EUR
Change Today -3.82 / -2.13%
Volume 32.0
As of 2:28 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILU) Snapshot

Open
€179.80
Previous Close
€179.54
Day High
€179.80
Day Low
€174.76
52 Week High
07/20/15 - €225.08
52 Week Low
10/15/14 - €106.98
Market Cap
25.4B
Average Volume 10 Days
273.4
EPS TTM
--
Shares Outstanding
144.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILU)

illumina inc (ILU) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic; and Burning Rock to develop molecular diagnostics for oncology. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $859.2K
President and Director
Total Annual Compensation: $689.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $463.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $403.7K
Compensation as of Fiscal Year 2014.

illumina inc (ILU) Key Developments

Burning Rock and Illumina, Inc. Collaborate on Molecular Diagnostics for Oncology

Burning Rock and Illumina Inc. announced they have entered into an agreement whereby Burning Rock will develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the ever-increasing importance of genomics to improve healthcare in China. In recent years, NGS has evolved rapidly and is widely regarded as an essential technology for enabling precision medicine. The collaboration between Burning Rock and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market by combining Illumina sequencing technology with Burning Rock’s advanced clinical application development capabilities. In particular, the two companies will work together to develop a user-friendly, oncology molecular diagnostic kit for the Chinese market. As part of the agreement, Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.

Illumina, Warburg Pincus And Sutter Hill Ventures Reportedly Invest In Helix

Illumina Inc. (NasdaqGS:ILMN), Warburg Pincus LLC and Sutter Hill Ventures have agreed to invest $100 million to seed HELIX OPCO LLC, according to people familiar with the deal. Illumina, Sutter Hill, LabCorp and Mayo did not immediately respond to requests for comment, reported Reuters.

Illumina Inc. Presents at UBS Genomics 2.0 Summit, Aug-12-2015 07:00 PM

Illumina Inc. Presents at UBS Genomics 2.0 Summit, Aug-12-2015 07:00 PM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: Jay T. Flatley, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILU:GR €175.72 EUR -3.82

ILU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $125.97 USD -1.65
Dr Reddy's Laboratories Ltd 4,286 INR -16.60
Hologic Inc $38.81 USD -0.95
Sigma-Aldrich Corp $139.41 USD -0.14
Waters Corp $121.38 USD -3.43
View Industry Companies
 

Industry Analysis

ILU

Industry Average

Valuation ILU Industry Range
Price/Earnings 61.7x
Price/Sales 14.0x
Price/Book 16.3x
Price/Cash Flow 55.2x
TEV/Sales 12.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.